Loading…
Loading…
TEM does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for TEM and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for TEM and 80,000+ other tickers.
See exactly how TEM's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for TEM and 80,000+ other tickers.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research…
Tempus AI is now a higher-conviction Buy after resolving prior concerns on MRD ownership and cash flow, with adjusted EBITDA turning positive. The Personalis acquisition secures MRD capabilities, integrating high-demand data and supporting pharma partnerships, while xT CDx FDA approval enables significant pricing uplift from 2027. The Data and Applications segment maintains robust ~28% growth, with a growing backlog and margins stabilizing despite headline deceleration and compute cost pressures.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio. With this agreement, BMS significantly expands its strategic relationship with Tempus and becomes one of Tempus's largest li.
NEW YORK--(BUSINESS WIRE)--Pathos AI, a clinical-stage AI and technology company advancing its own therapeutic pipeline, today announced multi-year strategic collaborations with Bristol Myers Squibb (NYSE: BMY, “BMS”) and Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) to build a specialized, curated dataset and agentic AI capabilities for Alzheimer's disease and other neurological conditions. BMS also leads Pathos's Series E financing and gains access to Pathos Foundry across its broader R&D portf.
Tempus AI delivers robust 22% YoY revenue growth, forecasting $1.6bn in 2026 and demonstrating strong commercial traction with Big Pharma partnerships. TEM's differentiated model leverages AI-driven diagnostics and data licensing, generating immediate revenues rather than relying on speculative milestone payments. Strategic acquisition of Personalis positions TEM to capitalize on the rapidly expanding minimal residual disease (MRD) cancer testing market.
As access to powerful general-purpose AI models expands, access alone offers limited differentiation. In precision healthcare, competitive advantage can come from combining proprietary clinical data, specialized models, and integration into diagnostic workflows.